Search

Your search keyword '"Yi, Jingbo"' showing total 26 results
Start Over Author "Yi, Jingbo"
26 results on '"Yi, Jingbo"'

5. Molecular basis of ClC-6 function and its impairment in human disease

Author

Zhang, Bing, primary, Zhang, Sensen, additional, Polovitskaya, Maya M., additional, Yi, Jingbo, additional, Ye, Binglu, additional, Li, Ruochong, additional, Huang, Xueying, additional, Yin, Jian, additional, Neuens, Sebastian, additional, Balfroid, Tom, additional, Soblet, Julie, additional, Vens, Daphné, additional, Aeby, Alec, additional, Li, Xiaoling, additional, Cai, Jinjin, additional, Song, Yingcai, additional, Li, Yuanxi, additional, Tartaglia, Marco, additional, Li, Yang, additional, Jentsch, Thomas J., additional, Yang, Maojun, additional, and Liu, Zhiqiang, additional

Published
2023
Full Text
View/download PDF

7. Molecular basis of ClC-6 function and its impairment in human disease

Author

Zhang, Bing, Zhang, Sensen, Polovitskaya, Maya M.M., Yi, Jingbo, Ye, Binglu, Li, Ruochong, Huang, Xueying, Yin, Jian, Neuens, Sebastian, Balfroid, Tom, Soblet, Julie, Vens, Daphné, Aeby, Alec, Li, Xiaoling, Cai, Jinjin, Song, Yingcai, Li, Yuanxi, Tartaglia, Marco, Li, Yang, Jentsch, Thomas T.J., Yang, Maojun, Liu, Zhiqiang, Zhang, Bing, Zhang, Sensen, Polovitskaya, Maya M.M., Yi, Jingbo, Ye, Binglu, Li, Ruochong, Huang, Xueying, Yin, Jian, Neuens, Sebastian, Balfroid, Tom, Soblet, Julie, Vens, Daphné, Aeby, Alec, Li, Xiaoling, Cai, Jinjin, Song, Yingcai, Li, Yuanxi, Tartaglia, Marco, Li, Yang, Jentsch, Thomas T.J., Yang, Maojun, and Liu, Zhiqiang

Abstract

ClC-6 is a late endosomal voltage-gated chloride-proton exchanger that is predominantly expressed in the nervous system. Mutated forms of ClC-6 are associated with severe neurological disease. However, the mechanistic role of ClC-6 in normal and pathological states remains largely unknown. Here, we present cryo-EM structures of ClC-6 that guided subsequent functional studies. Previously unrecognized ATP binding to cytosolic ClC-6 domains enhanced ion transport activity. Guided by a disease-causing mutation (p.Y553C), we identified an interaction network formed by Y553/F317/T520 as potential hotspot for disease-causing mutations. This was validated by the identification of a patient with a de novo pathogenic variant p.T520A. Extending these findings, we found contacts between intramembrane helices and connecting loops that modulate the voltage dependence of ClC-6 gating and constitute additional candidate regions for disease-associated gain-of-function mutations. Besides providing insights into the structure, function, and regulation of ClC-6, our work correctly predicts hotspots for CLCN6 mutations in neurodegenerative disorders., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

18. Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma.

Author

Nosaka, Kisato, Crawford, Bruce, Yi, Jingbo, Kuan, William, Matsumoto, Tomoko, and Takahashi, Takeshi

Subjects
SURVIVAL rate, HEMATOPOIETIC stem cell transplantation, HTLV, T cells, TREATMENT effectiveness
Abstract

Introduction: Adult T‐cell leukemia‐lymphoma (ATL) is a mature T‐cell lymphoproliferative neoplasm caused by human T‐cell leukemia virus type‐1 infection. There is no standard treatment for relapsed or refractory (r/r) ATL, and clinical outcomes are poor. This systematic review examined the survival outcomes for r/r ATL treated with various systemic therapies. Methods: EMBASE and PubMed were searched for studies on r/r ATL, published between January 2010 and January 2020. The main outcome of interest was overall survival (OS). Median OS and an exploratory 30% OS time were assessed based on published data and Kaplan‐Meier curves. Results: There were 21 unique treatment subgroups (from 14 studies), that met the eligibility criteria. Nine subgroups were mogamulizumab treatment, two were mogamulizumab prior to allogenic hematopoietic stem cell transplantation (allo‐HSCT), five were allo‐HSCT, and five were other chemotherapy. Respectively, the median OS and 30% OS varied considerably in range for mogamulizumab treatment (2.2–17.6 months and 8.7–27.1 months), allo‐HSCT (3.8–6.2 months and 7.5–19.8 months), and other chemotherapy arms (4.1–20.3 months and 7.1–17.0 months). Conclusion: Mogamulizumab was the most frequently studied treatment regimen and can potentially provide longer survival compared with chemotherapy alone. Future comparisons with synthetic or historical control arms may enable clearer insights into treatment efficacy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non–Muscle-invasive Bladder Cancer in United States Clinical Practice

Author

Richards, Kyle A., primary, Lin, Shih-Wen, additional, Chuo, Ching-Yi, additional, Derleth, Christina L., additional, Yi, Jingbo, additional, Zivkovic, Marko, additional, Ogale, Sarika, additional, Prasad, Sandip, additional, Decastro, G. Joel, additional, and Steinberg, Gary D., additional

Published
2020
Full Text
View/download PDF

26. PD18-09 INCREASED BACILLUS CALMETTE-GUÉRIN TREATMENT INTENSITY ASSOCIATED WITH IMPROVED OUTCOMES IN ELDERLY PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER

Author

Richards*, Kyle A., primary, Lin, Shih-Wen, additional, Chuo, Ching-Yi, additional, Derleth, Christina, additional, Yi, Jingbo, additional, Zivkovic, Marko, additional, Ogale, Sarika, additional, Prasad, Sandip, additional, Decastro, Guarionex J., additional, and Steinberg, Gary, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results